Apogee Therapeutics Logo
US03770N1019
APGE

Apogee Therapeutics

Prévisions

L'objectif de cours moyen des analystes est de 118,39 € (+1,54 %). La médiane est de 123,03 € (+5,52 %).

Acheter
  2
Conserver
  12
Vendre
  0

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Apogee Therapeutics reaches record high at $134.89

    Apogee Therapeutics' stock reached a record high of $134.89, representing a year-to-date gain of 256.92%. InvestingPro notes the stock may appear overvalued at this level and that its fair-value estimate is substantially lower. Apogee has more cash than debt but was unprofitable over the past twelve months. Shareholders approved AbbVie's acquisition, which values the company at $10.9 billion ($135.11 per share) and prompted analyst downgrades and adjusted price targets. » Plus sur de.investing.com


  • Apogee Therapeutics reaches record high at $134.47 ahead of takeover by AbbVie

    Apogee Therapeutics shares rose to an all-time high of $134.47 and show a year-to-date return of around 270% with a market capitalization of $10.08 billion. AbbVie announced an acquisition agreement at $135.11 per share, valuing Apogee at about $10.9 billion, while InvestingPro and RSI indicators point to overvaluation and overbought conditions. After the announcement, Mizuho and UBS downgraded the stock from buy to neutral, while RBC raised its price target to $97; Apogee also closed R&D agreements with Paragon Therapeutics and appointed new directors. » Plus sur de.investing.com


  • Apogee Therapeutics sold by Baron Capital after AbbVie agrees $135.11-per-share buyout

    Baron Health Care Fund sold its position in Apogee Therapeutics following AbbVie's announced acquisition of Apogee for $135.11 per share, a 49.5% premium to the prior close. The fund cited Apogee as a key contributor to its biotechnology stock selection during Q2 and reported overall quarterly gains. Apogee shares have risen sharply over the past year and the deal values the company at roughly $10.11 billion. » Plus sur finance.yahoo.com


  • Apogee Therapeutics reaches record high of $134.34

    Shares of Apogee Therapeutics rose to an all-time high of $134.34, about 243% above last year; market capitalization is roughly $10.05 billion. AbbVie announced a takeover agreement at $135.11 per share, valuing the company at about $10.9 billion, after which analysts at Mizuho and UBS downgraded the stock to "Neutral" and cited price targets around $135. Additional developments: a partnership with Paragon Therapeutics to develop an IL-31R antibody, an RBC price target of $97, and the move of zumilokibart into phase III trials. » Plus sur de.investing.com


  • Apogee Therapeutics reaches record high of $133.88 after takeover agreement with AbbVie

    Apogee Therapeutics' stock rose to a record high of $133.88, bringing market capitalization to about $10.02 billion. InvestingPro rates the stock as overvalued versus its fair value and notes an overbought RSI, despite strong performance (+250% over the past year). AbbVie announced a definitive takeover agreement at $135.11 per share (around $10.9 billion), after which several analysts downgraded their ratings to neutral and set price targets near $135. Additionally, Apogee announced collaboration agreements with Paragon Therapeutics to develop antibodies against the interleukin-31 receptor, and confirmed board elections and approved shareholder proposals. » Plus sur de.investing.com

Données financières

Au dernier trimestre, Apogee Therapeutics a réalisé un chiffre d'affaires de 0 € et un bénéfice net de -75,23 M €

(EUR) juin 2026
YoY
Chiffre d'affaires 0 -
Bénéfice brut 0 -
Bénéfice net -75,23 M 34,15 %
EBITDA -73,42 M 31,86 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
7,66 Md €
Nombre d'actions
62,2 M
Plus haut/bas sur 52 semaines
123,11 € - 32,25 €
Dividendes Non
Bêta
0,34
Ratio P/E
-31,12
Ratio PEG
6,57
Ratio P/B
8,53
Ratio P/S
0,00

Profil de l'entreprise

Apogee Therapeutics, Inc., par l'intermédiaire de sa filiale, exerce une activité de biotechnologie et développe des biologiques destinés au traitement de la dermatite atopique (DA), de la broncho-pneumopathie chronique obstructive (BPCO) et d'autres indications liées à l'inflammation et à l'immunologie. La société développe principalement l'APG777, un anticorps monoclonal (mAb) à demi-vie prolongée administré par voie sous-cutanée (SQ), pour la DA ; et l'APG808, un mAb à demi-vie prolongée administré par voie SQ, pour la BPCO. Ses programmes à un stade plus précoce comprennent l'APG990, un mAb à demi-vie prolongée administré par voie SQ, pour le traitement de la DA ; et l'APG222, des anticorps à demi-vie prolongée administrés par voie SQ, pour la DA. La société a été fondée en 2022 et est basée à Waltham, dans le Massachusetts.

Nom
Apogee Therapeutics
PDG
Michael Thomas Henderson
Siège social Waltham, ma
États-Unis
Site web
Industrie
Produits alimentaires
Introduction en bourse
14/07/2023
Employés 261

Symboles boursiers

Bourse Symbole
NASDAQ
APGE
🍪

Parqet  utilise des cookies. En savoir plus